Published in Cancer Weekly, September 20th, 2005
"Early detection of HCC through surveillance programs allows potentially curative therapies such as resection, liver transplantation and percutaneous ablation to be applied in 40% of the patients. In nonsurgical candidates, percutaneous treatments are the best therapeutic approach, and may improve survival in patients with well preserved liver function and small tumors that achieve initial complete response," scientists writing in the European Journal of Gastroenterology & Hepatology reported.
"Applying these criteria 5-year survival rates above 50% are achieved....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly